BioNexus Gene Lab

BioNexus Gene Lab Short-term Debt

The Short-Term Debt of BioNexus Gene Lab (BGLC) as of Oct 30, 2026 is 59,147.00 USD. In the previous year, Short-Term Debt was 50,816.00 USD — a change of 16.39% (higher).

Short-term Debt

59,147.00USD

YoY

16.39%

Last updated:

Short-Term Debt of BioNexus Gene Lab is 2025 59,147.00 USD. Short-Term Debt of BioNexus Gene Lab was 2024 50,816.00 USD. It decreases by 16.39% higher compared to the previous year.

The BioNexus Gene Lab Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
19,128.00 USD
Jan 1, 2019
32,137.00 USD
Jan 1, 2020
45,750.00 USD
Jan 1, 2021
39,507.00 USD
Jan 1, 2022
16,569.00 USD
Jan 1, 2023
47,831.00 USD
Jan 1, 2024
50,816.00 USD
Jan 1, 2025
59,147.00 USD
The BioNexus Gene Lab Short-term Debt history
YEARShort-term DebtYoY
59,147.00USD+16.39%
50,816.00USD+6.24%
47,831.00USD+188.68%
16,569.00USD-58.06%
39,507.00USD-13.65%
45,750.00USD+42.36%
32,137.00USD+68.01%
19,128.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

Short-Term Debt of BioNexus Gene Lab is 59,147.00 USD in 2025.

Short-Term Debt of BioNexus Gene Lab changed from 50,816.00 USD to 59,147.00 USD, representing a 16.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's BioNexus Gene Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioNexus Gene Lab

All Key Metrics — BioNexus Gene Lab